Literature DB >> 34080260

Phytochemical library screening reveals betulinic acid as a novel Skp2-SCF E3 ligase inhibitor in non-small cell lung cancer.

Dan-Hua He1,2, Yu-Fei Chen1,2, Yi-Le Zhou1, Shi-Bing Zhang1, Ming Hong1, Xianjun Yu3, Su-Fen Wei1, Xiang-Zhen Fan1, Si-Yi Li1, Qi Wang1, Yongzhi Lu4,5, Yong-Qiang Liu1,2.   

Abstract

Skp2 is overexpressed in multiple cancers and plays a critical role in tumor development through ubiquitin/proteasome-dependent degradation of its substrate proteins. Drugs targeting Skp2 have exhibited promising anticancer activity. Here, we identified a plant-derived Skp2 inhibitor, betulinic acid (BA), via high-throughput structure-based virtual screening of a phytochemical library. BA significantly inhibited the proliferation and migration of non-small cell lung cancer (NSCLC) through targeting Skp2-SCF E3 ligase both in vitro and in vivo. Mechanistically, BA binding to Skp2, especially forming H-bonds with residue Lys145, decreases its stability by disrupting Skp1-Skp2 interactions, thereby inhibiting the Skp2-SCF E3 ligase and promoting the accumulation of its substrates; that is, E-cadherin and p27. In both subcutaneous and orthotopic xenografts, BA significantly inhibited the proliferation and metastasis of NSCLC through targeting Skp2-SCF E3 ligase and upregulating p27 and E-cadherin protein levels. Taken together, BA can be considered a valuable therapeutic candidate to inhibit metastasis of NSCLC.
© 2021 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association.

Entities:  

Keywords:  E-cadherin; NSCLC; Skp2; betulinic acid; metastasis

Year:  2021        PMID: 34080260     DOI: 10.1111/cas.15005

Source DB:  PubMed          Journal:  Cancer Sci        ISSN: 1347-9032            Impact factor:   6.716


  3 in total

1.  A Ubiquitin-Proteasome Gene Signature for Predicting Prognosis in Patients With Lung Adenocarcinoma.

Authors:  Yunliang Tang; Yinhong Guo
Journal:  Front Genet       Date:  2022-05-31       Impact factor: 4.772

Review 2.  Research Status of Mouse Models for Non-Small-Cell Lung Cancer (NSCLC) and Antitumor Therapy of Traditional Chinese Medicine (TCM) in Mouse Models.

Authors:  Hongkui Chen; Min Zheng; Wenhui Zhang; Yuan Long; Yu Xu; Man Yuan
Journal:  Evid Based Complement Alternat Med       Date:  2022-09-21       Impact factor: 2.650

Review 3.  Potential of E3 Ubiquitin Ligases in Cancer Immunity: Opportunities and Challenges.

Authors:  Peng Ye; Xiaoxia Chi; Jong-Ho Cha; Shahang Luo; Guanghui Yang; Xiuwen Yan; Wen-Hao Yang
Journal:  Cells       Date:  2021-11-25       Impact factor: 6.600

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.